Impacting the Future of Human Health
Impacting the Future of Human Health

About Us



MABT was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.

Fundamentally, we are a speciality pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, primarily targeting the growing antibiotic resistance problem. MABT’s pioneering new Rabies therapy is the first to have received a valuable regulatory incentive called Orphan Drug Designation. Orphan Drug Designation offers one strategy for ensuring a more rapid, efficient pathway to FDA approval.

Home

Mid-Atlantic BioTherapeutics

Focus
Immunotherapy
Research

Antibiotic Resistance is Rapidly Growing

99
Anti-B Resistance
99
Cancer
99
Diabetes
99
Road Accidents

Our World is Changing

Fatality Rates
Fatality Rates
November 11, 2016
Rabies represents a niche, but medically important segment of the infectious disease market that, to date, has not been adequately served. Rabies is the most lethal organism known to the med...
Global Anti-Infectives Market
Global Anti-Infectives Market
November 11, 2016
Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$125 billion dollars in 20
Antibiotic Resistance
Antibiotic Resistance
November 10, 2016
Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 dea...

We're ready to change the world.

Visit Us On LinkedinVisit Us On Youtube